Immuneering (IMRX) Accumulated Expenses (2020 - 2024)
Historic Accumulated Expenses for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $4.6 million.
- Immuneering's Accumulated Expenses rose 3921.65% to $4.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.6 million, marking a year-over-year increase of 3921.65%. This contributed to the annual value of $5.2 million for FY2023, which is 1495.15% up from last year.
- As of Q3 2024, Immuneering's Accumulated Expenses stood at $4.6 million, which was up 3921.65% from $3.8 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Accumulated Expenses peaked at $5.2 million during Q4 2023, and registered a low of $698992.0 during Q4 2020.
- In the last 5 years, Immuneering's Accumulated Expenses had a median value of $3.3 million in 2021 and averaged $3.2 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 46730.94% in 2021, then crashed by 3290.83% in 2022.
- Over the past 5 years, Immuneering's Accumulated Expenses (Quarter) stood at $698992.0 in 2020, then soared by 467.31% to $4.0 million in 2021, then increased by 13.51% to $4.5 million in 2022, then grew by 14.95% to $5.2 million in 2023, then dropped by 11.23% to $4.6 million in 2024.
- Its Accumulated Expenses was $4.6 million in Q3 2024, compared to $3.8 million in Q2 2024 and $2.6 million in Q1 2024.